Positive updated phase II data with CAN-2409 in pancreatic cancer led shares of Candel Therapeutics Inc. (NASDAQ:CADL) to close April 4 at $6.40, up $4.72, or 281%, well above the firm’s previous 52-week high. At one point during the day, the stock had climbed to $7.65.
Top-line data from the phase II Kickstart study of Effector Therapeutics Inc.’s tomivosertib as a frontline treatment of non-small-cell lung cancer failed to produce data strong enough to continue development in the indication. The company has decided to halt the study, move ahead with a separate, investigator-sponsored study of tomivosertib in acute myeloid leukemia and focus on another drug in its pipeline for treating breast cancer. Effector’s stock (NASDAQ:EFTR) crumpled on the NCSLC news as shares plunged 82% on April 4 to close at $2.96 each. The closing value was the lowest the company has seen in the past 12 months.
Bridge Medicines LLC has divulged protein ENL (MLLT1; YEATS1) and/or FLT3 (FLK2/STK1) inhibitors potentially useful for the treatment of acute lymphocytic leukemia and acute myeloid leukemia.
Ono Pharmaceutical Co Ltd. has identified diacylglycerol kinase α (DGK-α, DGKA) and/or diacylglycerol kinase ζ (DGK-ζ, DGKZ) inhibitors reported to be useful for the treatment of cancer.
It has been previously demonstrated that while cancer cells with defects in ataxia telangiectasia mutated kinase (ATM) signaling are susceptible to ataxia telangiectasia and Rad3-related (ATR) inhibition following treatment with DNA-damaging drugs, normal cells can tolerate ATR inhibition by activating an ATM-mediated compensatory DNA damage response.
Conformation-X Therapeutics LLC has closed an oversubscribed funding tranche of $3.65 million to support the company’s development of a pipeline of immunotherapies that activate both the innate and adaptive arms of the immune system.
Verismo Therapeutics Inc. has submitted an IND application to the FDA seeking to initiate a phase I trial this year of Synkir-310 for the treatment of relapsed or refractory B-cell non-Hodgkin lymphomas (B-cell NHL), including diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma and marginal zone lymphoma.
Researchers from China Pharmaceutical University published data detailing the discovery and preclinical evaluation of novel tubulin polymerization inhibitors as potential anticancer agents.
Hypoxia-inducible factor 2α (HIF-2α) is a transcription factor that plays a key role in oxygen homeostasis and response to tumor hypoxic microenvironment of cancer cells. Previous research has suggested that inhibition of HIF-2α is a promising antitumor approach, particularly against tumors associated with mutant von Hippel-Lindau (pVHL).
RSS
